Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruyan Zhang

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Cancer Medicine|May 21, 2024
Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in ChinaHanfang Jiang, Jianxin Zhong, Jing Wang, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|January 6, 2019
Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II studyBin Shao, Guohong Song, Huiping Li, et al.
Frontiers in Oncology|July 3, 2023
Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world settingRuyan Zhang, Yifei Chen, Xiaoran Liu, et al.
Frontiers in Oncology|May 2, 2022
Germline Mutational Landscape in Chinese Patients With Advanced Breast CancerJiayang Zhang, Nan Wang, Tiantian Zheng, et al.
Current Oncology (Toronto, Ont.)|September 22, 2022
Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast CancerBin Shao, Xiaoran Liu, Huiping Li, et al.
Annals of Translational Medicine|February 23, 2023
The prognostic value of neutrophil-to-lymphocyte ratio in <i>de novo</i> stage IV breast cancer: a retrospective cohort studyBin Shao, Huiping Li, Xiaoran Liu, et al.
Breast Cancer Research and Treatment|March 6, 2023
Pegylated liposomal doxorubicin (Duomeisu<sup>®</sup>) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II studyHanfang Jiang, Huiping Li, Guohong Song, et al.
Cancer Medicine|August 4, 2021
Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016)Hanfang Jiang, Ruyan Zhang, Xiaoran Liu, et al.
American Journal of Cancer Research|October 17, 2018
Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancerHuiping Li, Yaping Xu, Fangyuan Zhao, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 27, 2018
Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancerXiaoran Liu, Ran Ran, Bin Shao, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Cancer Medicine|May 21, 2024
Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in ChinaHanfang Jiang, Jianxin Zhong, Jing Wang, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|January 6, 2019
Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II studyBin Shao, Guohong Song, Huiping Li, et al.
Frontiers in Oncology|July 3, 2023
Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world settingRuyan Zhang, Yifei Chen, Xiaoran Liu, et al.
Frontiers in Oncology|May 2, 2022
Germline Mutational Landscape in Chinese Patients With Advanced Breast CancerJiayang Zhang, Nan Wang, Tiantian Zheng, et al.
Current Oncology (Toronto, Ont.)|September 22, 2022
Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast CancerBin Shao, Xiaoran Liu, Huiping Li, et al.
Annals of Translational Medicine|February 23, 2023
The prognostic value of neutrophil-to-lymphocyte ratio in <i>de novo</i> stage IV breast cancer: a retrospective cohort studyBin Shao, Huiping Li, Xiaoran Liu, et al.
Breast Cancer Research and Treatment|March 6, 2023
Pegylated liposomal doxorubicin (Duomeisu<sup>®</sup>) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II studyHanfang Jiang, Huiping Li, Guohong Song, et al.
Cancer Medicine|August 4, 2021
Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016)Hanfang Jiang, Ruyan Zhang, Xiaoran Liu, et al.
American Journal of Cancer Research|October 17, 2018
Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancerHuiping Li, Yaping Xu, Fangyuan Zhao, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 27, 2018
Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancerXiaoran Liu, Ran Ran, Bin Shao, et al.
Pageof 6